{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T13:32:24Z","timestamp":1790775144233,"version":"4.1.0"},"reference-count":75,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["ITT"],"DOI":"10.2147\/itt.s240890","type":"journal-article","created":{"date-parts":[[2021,7,6]],"date-time":"2021-07-06T20:14:18Z","timestamp":1625602458000},"page":"237-246","source":"Crossref","is-referenced-by-count":13,"title":["Anti-CD52 Therapy for Multiple Sclerosis: An Update in the COVID Era"],"prefix":"10.2147","volume":"Volume 10","author":[{"given":"Kaja","family":"Kasarello","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dagmara","family":"Mirowska-Guzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2021,7]]},"reference":[{"key":"ref1","first-page":"325","volume":"7","author":"Domaga\u0142a","year":"2001","journal-title":"Med Sci Monit"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Treumann A, Lifely MR, Schneider P, Ferguson MA. Primary structure of CD52. J Biol Chem. 1995;270(11):6088\u201399. doi:10.1074\/jbc.270.11.6088.","DOI":"10.1074\/jbc.270.11.6088"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1007\/s00011-017-1032-8","volume":"66","author":"Zhao","year":"2017","journal-title":"Inflamm Res"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0039416","volume":"7","author":"Rao","year":"2012","journal-title":"PLoS One"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"3052","DOI":"10.1182\/blood-2009-02-203075","volume":"114","author":"Ambrose","year":"2009","journal-title":"Blood"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1084\/jem.189.6.979","volume":"189","author":"Masuyama","year":"1999","journal-title":"J Exp Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2006.05.006","author":"Watanabe","year":"2006","journal-title":"Clin Immunol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/7.1.69","author":"Rowan","year":"1995","journal-title":"Int Immunol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2019.01967","volume":"10","author":"Shathili","year":"2019","journal-title":"Front Immunol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1038\/ni.2610","volume":"14","author":"Bandala-Sanchez","year":"2013","journal-title":"Nat Immunol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"7783","DOI":"10.1073\/pnas.1722056115","volume":"115","author":"Bandala-Sanchez","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/cmi.2013.35","volume":"10","author":"Toh","year":"2013","journal-title":"Cell Mol Immunol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1038\/cdd.2017.173","volume":"25","author":"Rashidi","year":"2018","journal-title":"Cell Death Differ"},{"key":"ref14","first-page":"56","volume":"5","author":"Tati","year":"2016","journal-title":"Rep Biochem Mol Biol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1182\/blood.v62.4.873.873","volume":"62","author":"Hale","year":"1983","journal-title":"Blood"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1038\/332323a0","volume":"332","author":"Riechmann","year":"1988","journal-title":"Nature"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1080\/146532401753174098","author":"Hale","year":"2001","journal-title":"Cytotherapy"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1111\/j.1432-2277.2006.00382.x","author":"Lowenstein","year":"2006","journal-title":"Transpl Int"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1182\/blood-2002-04-1093","volume":"101","author":"Ratzinger","year":"2003","journal-title":"Blood"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1146\/annurev.immunol.23.021704.115707","volume":"23","author":"Sospedra","year":"2005","journal-title":"Annu Rev Immunol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1055\/s-0036-1579739","volume":"36","author":"Sospedra","year":"2016","journal-title":"Semin Neurol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2567.2009.03115.x","author":"Hu","year":"2009","journal-title":"Immunology"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12974-018-1263-9","volume":"15","author":"Simon","year":"2018","journal-title":"J Neuroinflammation"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.jneuroim.2015.05.018","volume":"285","author":"Turner","year":"2015","journal-title":"J Neuroimmunol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.jneuroim.2016.12.010","volume":"303","author":"Pant","year":"2017","journal-title":"J Neuroimmunol"},{"key":"ref26","author":"Avasarala","year":"2017","journal-title":"Innov Clin Neurosci"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1177\/2040622320947378","author":"Bogie","year":"2020","journal-title":"Ther Adv Chronic Dis"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"172923","DOI":"10.1016\/j.ejphar.2020.172923","volume":"871","author":"Ellwardt","year":"2020","journal-title":"Eur J Pharmacol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1177\/135245859600100616","author":"Moreau","year":"1996","journal-title":"Mult Scler"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2018.1425388","author":"Evana","year":"2018","journal-title":"Expert Opin Biol Ther"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000228","author":"Thomas","year":"2016","journal-title":"Neurol Neuroimmunol NeuroInflammation"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa0802670","author":"Coles","year":"2008","journal-title":"N Engl J Med"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-005-0934-5","author":"Coles","year":"2006","journal-title":"J Neurol"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awq176","author":"Jones","year":"2010","journal-title":"Brain"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000009097","author":"Delcoigne","year":"2020","journal-title":"Neurology"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200535075","author":"Cox","year":"2005","journal-title":"Eur J Immunol"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.169.7.3710","author":"Masuyama","year":"2002","journal-title":"J Immunol"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1301926","author":"Zhang","year":"2013","journal-title":"J Immunol"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-018-1334-y","author":"Kim","year":"2018","journal-title":"J Neuroinflammation"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2017.0676","author":"Baker","year":"2017","journal-title":"JAMA Neurol"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.3390\/cells9061396","author":"Rolla","year":"2020","journal-title":"Cells"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61769-3","author":"Cohen","year":"2012","journal-title":"Lancet"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61768-1","author":"Coles","year":"2012","journal-title":"Lancet"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.0000000000004313","author":"Havrdova","year":"2017","journal-title":"Neurology"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000004354","author":"Coles","year":"2017","journal-title":"Neurology"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1177\/1352458519881759","author":"Van Wijmeersch","year":"2020","journal-title":"Mult Scler J"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-020-09983-1","author":"Steingo","year":"2020","journal-title":"J Neurol"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"167","DOI":"10.2307\/j.ctvdf0dxq.12","author":"Michailidou","year":"2019","journal-title":"Internet Eur Integr"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1177\/1756285617722706","author":"Ziemssen","year":"2017","journal-title":"Ther Adv Neurol Disord"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2019.00253","author":"Barclay","year":"2019","journal-title":"Front Neurol"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1186\/s42466-019-0045-x","author":"Bierhansl","year":"2019","journal-title":"Neurol Res Pract"},{"key":"ref52","unstructured":"Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 8\u201311 April 2019. European Medicines Agency. Availabvle from: https:\/\/www.ema.europa.eu\/en\/news\/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-8-11-april-2019. Accessed May 27, 2021."},{"key":"ref53","unstructured":"Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 28\u201331 October 2019. European Medicines Agency. Availabvle from: https:\/\/www.ema.europa.eu\/en\/news\/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-28-31-october-2019. Accessed May 27, 2021."},{"key":"ref54","unstructured":"CHMP. Lemtrada; INN: alemtuzumab. Availabvle from: www.ema.europa.eu\/contact. Accessed February 15, 2021."},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2018.1483330","author":"Buonomo","year":"2018","journal-title":"Expert Opin Drug Saf"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30628-0","author":"Mehta","year":"2020","journal-title":"Lancet"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30691-7","author":"Ritchie","year":"2020","journal-title":"Lancet"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30566-3","author":"Zhou","year":"2020","journal-title":"Lancet"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-020-00756-y","author":"Zheng","year":"2020","journal-title":"CNS Drugs"},{"key":"ref60","unstructured":"FDA warns about rare but serious risks of stroke and blood vessel wall tears with multiple sclerosis drug Lemtrada (alemtuzumab). FDA. Availabvle from: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-warns-about-rare-serious-risks-stroke-and-blood-vessel-wall-tears-multiple-sclerosis-drug. Accessed February 15, 2021."},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1056\/nejmc2009787","author":"Oxley","year":"2020","journal-title":"N Engl J Med"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000009507","author":"Brownlee","year":"2020","journal-title":"Neurology"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1177\/1352458520926459","author":"Carandini","year":"2020","journal-title":"Mult Scler J"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102402","author":"Fern\u00e1ndez-D\u00edaz","year":"2020","journal-title":"Mult Scler Relat Disord"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102314","author":"Guevara","year":"2020","journal-title":"Mult Scler Relat Disord"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102297","author":"Mat\u00edas-Guiu","year":"2020","journal-title":"Mult Scler Relat Disord"},{"key":"ref67","doi-asserted-by":"publisher","first-page":"102447","DOI":"10.1016\/j.msard.2020.102447","volume":"46","author":"Fiorella","year":"2020","journal-title":"Mult Scler Relat Disord"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000835","author":"Parrotta","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"ref69","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cit684","author":"Rubin","year":"2014","journal-title":"Clin Infect Dis"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.1177\/1352458520952310","author":"Riva","year":"2020","journal-title":"Mult Scler J"},{"key":"ref71","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102439","author":"Ciotti","year":"2020","journal-title":"Mult Scler Relat Disord"},{"key":"ref72","unstructured":"European Medicines Agency. Annex I; Summary of Product Characteristics: Comirnaty concentrate for dispersion for injection; COVID-19 mRNA Vaccine (nucleoside modified); 2020. Available from: https:\/\/ec.europa.eu\/health\/documents\/community-register\/2020\/20201221150522\/anx_150522_en.pdf. Accessed June 29, 2021."},{"key":"ref73","unstructured":"European Medicines Agency. Annex I; Summary of Product Characteristics: COVID-19 Vaccine Moderna dispersion for injection; COVID-19 mRNA Vaccine (nucleoside modified); 2020. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/covid-19-vaccine-moderna-epar-product-information_en.pdf. Access June 29, 2021."},{"key":"ref74","unstructured":"European Medicines Agency. Annex I; Summary of Product Characteristics: COVID-19 Vaccine AstraZeneca suspension for injection; COVID-19 Vaccine (ChAdOx1-S [recombinant]); 2021. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/covid-19-vaccine-astrazeneca-product-information-approved-chmp-29-january-2021-pending-endorsement_en.pdf. Accessed June 29, 2021."},{"key":"ref75","unstructured":"European Medicines Agency. Annex I; Summary of Product Characteristics: COVID-19 Vaccine Janssen suspension for injection; COVID-19 vaccine (Ad26.COV2-S [recombinant]); 2021. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/covid-19-vaccine-janssen-epar-product-information_en.pdf. Accessed June 29, 2021."}],"container-title":["ImmunoTargets and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=71418","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=71418","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,6]],"date-time":"2021-07-06T20:14:33Z","timestamp":1625602473000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dovepress.com\/anti-cd52-therapy-for-multiple-sclerosis-an-update-in-the-covid-era-peer-reviewed-fulltext-article-ITT"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":75,"URL":"https:\/\/doi.org\/10.2147\/itt.s240890","relation":{},"ISSN":["2253-1556"],"issn-type":[{"value":"2253-1556","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7]]}}}